Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Recipients Of HIV/AIDS Programs Aid Expected To Feel Crunch Of Global Economic Crisis
At the 2009 HIV Implementers" Meeting in Namibia Thursday, Paul DeLay, deputy executive director of UNAIDS, said the global economic crisis will impact countries who receive international aid for HIV/AIDS programs, so recipients of such aid should identify priorities for their programs, the China Post reports (China Post, 6/12).

Report Looks At HIV Prevalence Among Chicago Gay Men
In Chicago, 17.4 percent of gay men are estimated to be HIV-positive, compared with 1.2 percent of the general male population, according to a new report by the Chicago Public Health Department, the Chicago Sun-Times reports. The report is based on data collected from 570 Chicago men through the National HIV Behavioral Surveillance system, and found that half of the men with HIV were unaware they were infected (Thomas, 7/25). "Health officials said Friday, information in the report on HIV infection mark the first time Chicago health officials have used blood-testing to determine infection rates among men," the AP/Chicago Tribune reports. In the past, estimates have relied on interviews with gay and bisexual men, according to Christopher Brown, the Public Health Department assistant commissioner. The report also found that "black men who have sex with other men have double the HIV infection rates of white and Hispanic men," the AP/Tribune reports (7/24).
News of the day
ImmuneRegen BioSciences Confirms Homspera's Therapeutic Anti-Influenza Effect On Pandemic H1N1 Influenza Virus After Oral Administration
ImmuneRegen BioSciences(R), a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTC Bulletin Board: IRBS), reports preliminary evidence that its selective Neurokinin 1-receptor agonist Homspera(R) is both active on oral administration and provides therapeutic effects against the current pandemic H1N1 virus infection.
Sexual Health

Carbapenems And Other Agents That Provide Broad-Spectrum Activity Are Preferred By Surveyed Physicians For The Treatment Of Intra-Abdominal Infections

Arlington Medical Res (AMR) and Decision Res find that surveyed physicians will increase prescribing of Wyeth"s Tygacil, Merck"s Invanz and Johnson & Johnson"s Doribax in the next five years for the treatment of intra-abdominal infections because of their potent broad-spectrum activity and efficacy against gram-negative and anaerobic organisms. "Treatment for intra-abdominal infections is largely empiric," stated Lisa Arias, analyst at Decision Res. "A variety of organisms, particularly gram-negative aerobic bacteria and anaerobes, are documented in patients with an intra-abdominal infection. In fact, the leading attribute that physicians surveyed look for in a drug to treat intra-abdominal infections is its activity against anaerobes." The new report entitled Hospital Anti-Infectives Insight Series: Intra-Abdominal Infections also finds that 96 percent of surveyed physicians cite a drug"s activity against anaerobes as the leading attribute in antibiotic selection. Intra-abdominal infections are often polymicrobial in nature and involve anaerobes specific to the etiology of the infection, so activity against these organisms is advantageous even without bacterial confirmation. "Physicians also rank availability in intravenous formulation and a low propensity to induce resistance as other important drug attributes that influence their selection in antibiotics," added Ms. Arias. "While some agents with anaerobic and gram negative activity, such as carbapenems, address some of these attributes, no antibiotic captures all of the top most important attributes which leaves opportunity for novel products to differentiate themselves." About Hospital Anti-Infectives Insight Series AMR and Decision Res" Hospital Anti-Infectives Insight Series analyzes hospital antibiotic prescribing patterns using AMR"s comprehensive and highly detailed clinical data in conjunction with Decision Res" disease area knowledge, primary research and extensive understanding of emerging therapies and forecasts. These reports examine the reasons behind physicians" product preferences, factors driving hospital antibiotic prescribing patterns and receptivity to emerging antibiotics. About AMR AMR serves the market intelligence needs of the pharmaceutical and diagnostic imaging industries. Research includes clinical inpatient databases that directly link anti-infective drug with indication/procedure, formulary and stocking status tracking studies, drug purchasing audits and diagnostic imaging procedure volume/contrast media usage audits. AMR is a Decision Res, Inc. company. About Decision Res Decision Res is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate res and master their chosen markets. Decision Res is a Decision Res, Inc. company. About Decision Res, Inc. Decision Res, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders. Decision Res


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009